EBMT NEWSLETTER | March 2017 | Volume 56 - Issue 2

Important dates
We are pleased to announce the launch of a new independent educational resource created by Springer Healthcare IME for the rare disease, Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID).
New Horizons in the Management of ADA-SCID www.ada-scid.online is an independent initiative steered by an editorial board of multidisciplinary experts: Andrew Gennery, Bobby Gaspar and Robbert Bredius. It is designed to educate healthcare professionals who are presented with ADA-SCID patients, in the biology of the disease, how to screen for it, and current and emerging treatments.
New Horizons in the Management of ADA-SCID aims to facilitate this understanding by providing direct access to the latest research and commentary in the form of:
  • Summaries of the latest research
  • Access to full text articles
  • Interviews with the leading experts
  • A live and on-demand webinar
  • Interactive patient-case studies
  • A review of ADA-SCID from the Orphanet Journal of Rare Diseases
Please visit the site today and sign up to receive an email alert when more educational content is added.
New Horizons in the Management of ADA-SCID is produced by Springer Healthcare IME. This educational activity is supported by an educational grant from GlaxoSmithKline.
Bios and Disclosures:
Dr Andrew Gennery, Watson Reader/Honorary Consultant in Paediatric Immunology & Haematopoeitic Stem Cell Transplantation. Newcastle University and Great North Children’s Hospital, Newcastle upon Tyne, UK.
Dr Gennery has delivered lectures as part of an ‘in- house’ education staff to GSK Staff – Haematopoietic Stem Cell Transplantation for Primary Immunodeficiencies.
Professor Bobby Gaspar, Professor of Paediatrics and Immunology; Consultant in Paediatric Immunology; Head, Rare Diseases Theme; Head, Molecular and Cellular Immunology Section. UCL Great Ormond Street Institute of Child Health, UK.
Professor Gaspar is founder and Chief Scientific Officer for Orchard Therapeutics, a new company that is developing a lentiviral gene therapy approach for ADA-SCID.
Dr Robbert Bredius, MD PhD, Paediatric Immunologist – Infectious Disease – Stem Cell Transplant Dr. Department of Paediatrics, Immunology section, Hematology and Stem Cell Transplantation, Leiden University Medical Centre, The Netherlands.
Dr Bredius has delivered industry symposia presentations funded by GSK.
Bookmark and Share